Technology Bundle ID
TAB-3599

Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection

Applications
Linked ID
E-202-2016-0
Lead Inventors
Wei Zheng (NCATS)
Co-Inventors
Cheng YiChen (Florida State University Research Foundation, Inc.)
Emily Lee (Florida State University Research Foundation, Inc.)
Guo-Li Ming (Johns Hopkins University)
Hengli Tang (Florida State University Research Foundation, Inc.)
Hongjun Song (Johns Hopkins University)
Miao Xu (NCATS)
Ruili Huang (NCATS)
Wenwei Huang (NCATS)
Yi Zhou (Florida State University Research Foundation, Inc.)
Zhexing Wen (Johns Hopkins University)
ICs
This invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug discovery and development.
Commercial Applications
The group of identified CDK inhibitors could be used with an animal model to test for in vivo efficacy and to optimize the chemistry of the lead compounds.
Competitive Advantages
Repurposing CDK inhibitors that have been used in clinical trials for other diseases for the treatment of Zika virus infection can reduce the long time course needed for new drug discovery and development.

Request More Info

Licensing Contact: